{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:38:05Z","timestamp":1794580685314,"version":"4.9.1"},"reference-count":164,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.tem.2021.03.007","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T16:11:14Z","timestamp":1618848674000},"page":"382-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management"],"prefix":"10.1016","volume":"32","author":[{"given":"Thomas","family":"Siff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parash","family":"Parajuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"Razzaque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeddine","family":"Atfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2021.03.007_bb0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fonc.2020.00298","article-title":"Management of cancer cachexia: attempting to develop new pharmacological agents for new effective therapeutic options","volume":"10","author":"Marceca","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tem.2021.03.007_bb0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2021.03.007_bb0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tem.2021.03.007_bb0020","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.clnu.2014.03.007","article-title":"Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia","volume":"33","author":"Biolo","year":"2014","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.tem.2021.03.007_bb0025","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.tem.2021.03.007_bb0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2015.09.001","article-title":"Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes","volume":"54","author":"Kazemi-Bajestani","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.tem.2021.03.007_bb0035","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.4081\/ejtm.2018.7590","article-title":"Chemotherapy-induced muscle wasting: association with NF-kappaB and cancer cachexia","volume":"28","author":"Damrauer","year":"2018","journal-title":"Eur. J. Transl. Myol."},{"key":"10.1016\/j.tem.2021.03.007_bb0040","doi-asserted-by":"crossref","first-page":"43442","DOI":"10.18632\/oncotarget.9779","article-title":"Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1\/2 and p38 MAPKs","volume":"7","author":"Barreto","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tem.2021.03.007_bb0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/mus.21809","article-title":"Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy","volume":"43","author":"Gilliam","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tem.2021.03.007_bb0050","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3390\/jcm8081211","article-title":"Nutrition in cancer patients","volume":"8","author":"Ravasco","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tem.2021.03.007_bb0055","first-page":"23","article-title":"The evolving approach to management of cancer cachexia","volume":"31","author":"Dev","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.tem.2021.03.007_bb0060","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.tem.2021.03.007_bb0065","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/jcsm.12184","article-title":"C-reactive protein, symptoms and activity of daily living in patients with advanced cancer receiving palliative care","volume":"8","author":"Amano","year":"2017","journal-title":"J. Cachex. Sarcopenia Muscle"},{"key":"10.1016\/j.tem.2021.03.007_bb0070","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1078-0432.CCR-11-2133","article-title":"Suppression of skeletal muscle turnover in cancer cachexia: evidence from the transcriptome in sequential human muscle biopsies","volume":"18","author":"Gallagher","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tem.2021.03.007_bb0075","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/jcsm.12138","article-title":"New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss","volume":"8","author":"Johns","year":"2017","journal-title":"J. Cachex. Sarcopenia Muscle"},{"key":"10.1016\/j.tem.2021.03.007_bb0080","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: a double-edged sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tem.2021.03.007_bb0085","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1126\/science.289.5488.2363","article-title":"NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia","volume":"289","author":"Guttridge","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.tem.2021.03.007_bb0090","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2337\/diabetes.51.5.1319","article-title":"Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory","volume":"51","author":"Ruan","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.tem.2021.03.007_bb0095","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1172\/JCI200420174","article-title":"Cancer cachexia is regulated by selective targeting of skeletal muscle gene products","volume":"114","author":"Acharyya","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2021.03.007_bb0100","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.cell.2015.08.031","article-title":"Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival","volume":"162","author":"Johnston","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.tem.2021.03.007_bb0105","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/jcp.22821","article-title":"TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases","volume":"227","author":"Bhatnagar","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.tem.2021.03.007_bb0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2004.09.027","article-title":"IKKbeta\/NF-kappaB activation causes severe muscle wasting in mice","volume":"119","author":"Cai","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.tem.2021.03.007_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024650","article-title":"The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min\/+) mouse","volume":"6","author":"White","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tem.2021.03.007_bb0120","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.molmed.2017.03.001","article-title":"Connecting the metabolic and immune responses to cancer","volume":"23","author":"Flint","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tem.2021.03.007_bb0125","doi-asserted-by":"crossref","first-page":"19976-1986","DOI":"10.1074\/jbc.M115.638411","article-title":"A key role for leukemia inhibitory factor in C26 cancer cachexia","volume":"290","author":"Seto","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2021.03.007_bb0130","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121221","article-title":"Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin","volume":"3","author":"Arora","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.tem.2021.03.007_bb0135","first-page":"R659","article-title":"Cachectin\/TNF or IL-1 alpha induces cachexia with redistribution of body proteins","volume":"256","author":"Fong","year":"1989","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.tem.2021.03.007_bb0140","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1084\/jem.20111020","article-title":"Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis","volume":"208","author":"Braun","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tem.2021.03.007_bb0145","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41568-020-0251-4","article-title":"Understanding cachexia in the context of metastatic progression","volume":"20","author":"Biswas","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0150","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1126\/science.1069525","article-title":"Induction of cachexia in mice by systemically administered myostatin","volume":"296","author":"Zimmers","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.tem.2021.03.007_bb0155","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","author":"Argiles","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0160","doi-asserted-by":"crossref","first-page":"12448","DOI":"10.1073\/pnas.1707925114","article-title":"Blockade of activin type II receptors with a dual anti-ActRIIA\/IIB antibody is critical to promote maximal skeletal muscle hypertrophy","volume":"114","author":"Morvan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2021.03.007_bb0165","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1210\/jc.2014-4318","article-title":"Role of Activin A and myostatin in human cancer cachexia","volume":"100","author":"Loumaye","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2021.03.007_bb0170","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1096\/fj.13-245894","article-title":"Elevated expression of activins promotes muscle wasting and cachexia","volume":"28","author":"Chen","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.tem.2021.03.007_bb0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00395-017-0639-9","article-title":"Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting","volume":"112","author":"Zimmers","year":"2017","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.tem.2021.03.007_bb0180","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature24042","article-title":"Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15","volume":"550","author":"Hsu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.tem.2021.03.007_bb0185","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm.4394","article-title":"GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand","volume":"23","author":"Yang","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.tem.2021.03.007_bb0190","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41467-017-00726-x","article-title":"Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tem.2021.03.007_bb0195","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1053\/j.gastro.2018.10.026","article-title":"ZIP4 promotes muscle wasting and cachexia in mice with orthotopic pancreatic tumors by stimulating RAB27B-regulated release of extracellular vesicles from cancer cells","volume":"156","author":"Yang","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tem.2021.03.007_bb0200","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1073\/pnas.1402714111","article-title":"Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7","volume":"111","author":"He","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2021.03.007_bb0205","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1158\/0008-5472.CAN-17-3878","article-title":"The TLR7\/8\/9 antagonist IMO-8503 inhibits cancer-induced cachexia","volume":"78","author":"Calore","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.tem.2021.03.007_bb0210","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00184-19","article-title":"The Toll-like receptor\/MyD88\/XBP1 signaling axis mediates skeletal muscle wasting during cancer cachexia","volume":"39","author":"Bohnert","year":"2019","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.tem.2021.03.007_bb0215","first-page":"4138","article-title":"Role of prostaglandins in the production of hypercalcemia by tumors","volume":"38","author":"Tashjian","year":"1978","journal-title":"Cancer Res."},{"key":"10.1016\/j.tem.2021.03.007_bb0220","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature13528","article-title":"Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia","volume":"513","author":"Kir","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.tem.2021.03.007_bb0225","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","article-title":"PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer","volume":"23","author":"Kir","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.tem.2021.03.007_bb0230","first-page":"3347","article-title":"Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer","volume":"45","author":"Evans","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.tem.2021.03.007_bb0235","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.tem.2021.03.007_bb0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12976-015-0015-0","article-title":"Modeling the energetic cost of cancer as a result of altered energy metabolism: implications for cachexia","volume":"12","author":"Friesen","year":"2015","journal-title":"Theor. Biol. Med. Model."},{"key":"10.1016\/j.tem.2021.03.007_bb0245","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.2741\/2293","article-title":"Targets in clinical oncology: the metabolic environment of the patient","volume":"12","author":"Argiles","year":"2007","journal-title":"Front. Biosci."},{"key":"10.1016\/j.tem.2021.03.007_bb0250","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s13539-014-0154-x","article-title":"Cachexia: a problem of energetic inefficiency","volume":"5","author":"Argiles","year":"2014","journal-title":"J. Cachex. Sarcopenia Muscle"},{"key":"10.1016\/j.tem.2021.03.007_bb0255","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1126\/science.167.3920.1003","article-title":"Alanine: key role in gluconeogenesis","volume":"167","author":"Felig","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.tem.2021.03.007_bb0260","doi-asserted-by":"crossref","first-page":"E743","DOI":"10.1073\/pnas.1714703115","article-title":"Fenofibrate prevents skeletal muscle loss in mice with lung cancer","volume":"115","author":"Goncalves","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2021.03.007_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-07-0606","article-title":"Mechanisms of glucocorticoid-induced myopathy","volume":"197","author":"Schakman","year":"2008","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.tem.2021.03.007_bb0270","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.tem.2021.03.007_bb0275","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00000658-199404000-00001","article-title":"Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer","volume":"219","author":"Falconer","year":"1994","journal-title":"Ann. Surg."},{"key":"10.1016\/j.tem.2021.03.007_bb0280","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1006\/jsre.1993.1192","article-title":"Acute-phase proteins in response to tumor growth","volume":"55","author":"Andersson","year":"1993","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.tem.2021.03.007_bb0285","first-page":"265","article-title":"Systemic inflammation, cachexia and prognosis in patients with cancer","volume":"8","author":"Deans","year":"2005","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.tem.2021.03.007_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022538","article-title":"STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia","volume":"6","author":"Bonetto","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tem.2021.03.007_bb0295","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/med.20010","article-title":"Cross-talk between skeletal muscle and adipose tissue: a link with obesity?","volume":"25","author":"Argiles","year":"2005","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.tem.2021.03.007_bb0300","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12944-018-0657-0","article-title":"Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning","volume":"17","author":"Han","year":"2018","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.tem.2021.03.007_bb0305","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.bjc.6606083","article-title":"Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients","volume":"104","author":"Mracek","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0310","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ecl.2013.10.005","article-title":"Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism","volume":"43","author":"Geer","year":"2014","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.tem.2021.03.007_bb0315","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/1535370216683282","article-title":"The role of adipose tissue in cancer-associated cachexia","volume":"242","author":"Vaitkus","year":"2017","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.tem.2021.03.007_bb0320","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","article-title":"A switch from white to brown fat increases energy expenditure in cancer-associated cachexia","volume":"20","author":"Petruzzelli","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.tem.2021.03.007_bb0325","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4103\/0019-509X.175828","volume":"52","author":"Basu","year":"2015","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0330","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41574-018-0123-0","article-title":"Inter-tissue communication in cancer cachexia","volume":"15","author":"Argiles","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.tem.2021.03.007_bb0335","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00535-013-0787-0","article-title":"Cancer cachexia--pathophysiology and management","volume":"48","author":"Suzuki","year":"2013","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.tem.2021.03.007_bb0340","first-page":"2635","article-title":"Characteristics of taste and smell alterations reported by patients after starting treatment for lung cancer","volume":"22","author":"McGreevy","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0345","first-page":"250","article-title":"Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity","volume":"14","author":"Prado","year":"2011","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.tem.2021.03.007_bb0350","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jpainsymman.2012.06.020","article-title":"Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis","volume":"46","author":"Oberholzer","year":"2013","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.tem.2021.03.007_bb0355","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jcsm.12033","article-title":"Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients","volume":"6","author":"Lerner","year":"2015","journal-title":"J. Cachex. Sarcopenia Muscle"},{"key":"10.1016\/j.tem.2021.03.007_bb0360","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4939-2895-8_7","article-title":"Glucocorticoids and skeletal muscle","volume":"872","author":"Bodine","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.tem.2021.03.007_bb0365","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.peptides.2006.11.021","article-title":"Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice","volume":"28","author":"Joppa","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.tem.2021.03.007_bb0370","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/path.4546","article-title":"Soluble factors regulated by epithelial-mesenchymal transition mediate tumour angiogenesis and myeloid cell recruitment","volume":"236","author":"Suarez-Carmona","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.tem.2021.03.007_bb0375","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.devcel.2018.05.026","article-title":"Twist1 activation in muscle progenitor cells causes muscle loss akin to cancer cachexia","volume":"45","author":"Parajuli","year":"2018","journal-title":"Dev. Cell"},{"key":"10.1016\/j.tem.2021.03.007_bb0380","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/ncb1507","article-title":"Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis","volume":"8","author":"Hiratsuka","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.tem.2021.03.007_bb0385","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature07623","article-title":"Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis","volume":"457","author":"Kim","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.tem.2021.03.007_bb0390","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI3523","article-title":"TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development","volume":"103","author":"Yin","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2021.03.007_bb0395","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1038\/s41388-019-0736-3","article-title":"Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.tem.2021.03.007_bb0400","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10585-006-9010-5","article-title":"Activin A circulating levels in patients with bone metastasis from breast or prostate cancer","volume":"23","author":"Leto","year":"2006","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.tem.2021.03.007_bb0405","doi-asserted-by":"crossref","first-page":"7587","DOI":"10.4081\/ejtm.2018.7587","article-title":"Chemotherapy-induced muscle wasting: an update","volume":"28","author":"Coletti","year":"2018","journal-title":"Eur. J. Transl. Myol."},{"key":"10.1016\/j.tem.2021.03.007_bb0410","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.clnu.2016.12.003","article-title":"Association between cachexia, chemotherapy and outcomes in older cancer patients: a systematic review","volume":"36","author":"Caillet","year":"2017","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.tem.2021.03.007_bb0415","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1586\/14737140.2.1.121","article-title":"Anticancer drugs that induce cancer-associated cachectic syndromes","volume":"2","author":"Tohgo","year":"2002","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.tem.2021.03.007_bb0420","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/jcsm.12360","article-title":"Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism","volume":"10","author":"Pin","year":"2019","journal-title":"J. Cachex. Sarcopenia Muscle"},{"key":"10.1016\/j.tem.2021.03.007_bb0425","doi-asserted-by":"crossref","first-page":"7947596","DOI":"10.1155\/2019\/7947596","article-title":"Elevation of IL-6 and IL-33 levels in serum associated with lung fibrosis and skeletal muscle wasting in a bleomycin-induced lung injury mouse model","volume":"2019","author":"Shieh","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.tem.2021.03.007_bb0430","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.biocel.2013.06.021","article-title":"Muscle wasting: the gut microbiota as a new therapeutic target?","volume":"45","author":"Bindels","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.tem.2021.03.007_bb0435","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1096\/fj.10-164152","article-title":"Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways","volume":"25","author":"Doyle","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.tem.2021.03.007_bb0440","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1073\/pnas.0605374104","article-title":"Mechanisms underlying the resistance to diet-induced obesity in germ-free mice","volume":"104","author":"Backhed","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2021.03.007_bb0445","first-page":"236","article-title":"Acylated and unacylated ghrelin administration to blunt muscle wasting","volume":"17","author":"Reano","year":"2014","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.tem.2021.03.007_bb0450","first-page":"1387","article-title":"Acylated and unacylated ghrelin inhibit apoptosis in myoblasts cocultured with colon carcinoma cells","volume":"39","author":"Zeng","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tem.2021.03.007_bb0455","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1210\/en.2002-220783","article-title":"The role of ghrelin and growth hormone secretagogues receptor on rat adipogenesis","volume":"144","author":"Choi","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2021.03.007_bb0460","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.regpep.2009.11.010","article-title":"Genetic suppression of ghrelin receptors activates brown adipocyte function and decreases fat storage in rats","volume":"160","author":"Mano-Otagiri","year":"2010","journal-title":"Regul. Pept."},{"key":"10.1016\/j.tem.2021.03.007_bb0465","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.mehy.2015.09.008","article-title":"A hypothesis for a possible synergy between ghrelin and exercise in patients with cachexia: biochemical and physiological bases","volume":"85","author":"Fuoco","year":"2015","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.tem.2021.03.007_bb0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173113","article-title":"Development of ghrelin resistance in a cancer cachexia rat model using human gastric cancer-derived 85As2 cells and the palliative effects of the Kampo medicine rikkunshito on the model","volume":"12","author":"Terawaki","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.tem.2021.03.007_bb0475","first-page":"1651","article-title":"Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis","volume":"25","author":"Bai","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0480","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2478\/v10181-011-0133-5","article-title":"A role of ghrelin in cancerogenesis","volume":"15","author":"Majchrzak","year":"2012","journal-title":"Pol. J. Vet. Sci."},{"key":"10.1016\/j.tem.2021.03.007_bb0485","first-page":"15","article-title":"Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia","volume":"27","author":"Constantinou","year":"2011","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.tem.2021.03.007_bb0490","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.febslet.2004.12.050","article-title":"Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia","volume":"579","author":"Busquets","year":"2005","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tem.2021.03.007_bb0495","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/sj.bjc.6600074","article-title":"Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans","volume":"86","author":"Collins","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0500","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nrm1592","article-title":"The mitochondrial uncoupling-protein homologues","volume":"6","author":"Krauss","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.tem.2021.03.007_bb0505","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0014-5793(01)02815-0","article-title":"Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?","volume":"505","author":"Busquets","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tem.2021.03.007_bb0510","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S1097-2765(01)00390-2","article-title":"Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1","volume":"8","author":"Puigserver","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tem.2021.03.007_bb0515","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1158\/0008-5472.CAN-07-0231","article-title":"Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists","volume":"67","author":"Fuster","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.tem.2021.03.007_bb0520","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2353\/ajpath.2006.060034","article-title":"Overexpression of peroxisome proliferator-activated receptor gamma co-activator-1alpha leads to muscle atrophy with depletion of ATP","volume":"169","author":"Miura","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tem.2021.03.007_bb0525","doi-asserted-by":"crossref","first-page":"16260","DOI":"10.1073\/pnas.0607795103","article-title":"PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription","volume":"103","author":"Sandri","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2021.03.007_bb0530","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1139\/H09-049","article-title":"Regulation of mitofusin-2 expression in skeletal muscle","volume":"34","author":"Zorzano","year":"2009","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"10.1016\/j.tem.2021.03.007_bb0535","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejcb.2007.04.002","article-title":"Mitochondrial clustering induced by overexpression of the mitochondrial fusion protein Mfn2 causes mitochondrial dysfunction and cell death","volume":"86","author":"Huang","year":"2007","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.tem.2021.03.007_bb0540","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/j.bbagen.2012.11.009","article-title":"Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency?","volume":"1830","author":"Fontes-Oliveira","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tem.2021.03.007_bb0545","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JES.0b013e3181911fa4","article-title":"Sarcoplasmic reticulum-mitochondrial symbiosis: bidirectional signaling in skeletal muscle","volume":"37","author":"Rossi","year":"2009","journal-title":"Exerc. Sport Sci. Rev."},{"key":"10.1016\/j.tem.2021.03.007_bb0550","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/mus.21893","article-title":"Calpain activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss","volume":"43","author":"Smith","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tem.2021.03.007_bb0555","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3945\/ajcn.113.063859","article-title":"Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients","volume":"98","author":"Tardif","year":"2013","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.tem.2021.03.007_bb0560","doi-asserted-by":"crossref","first-page":"30340","DOI":"10.1038\/srep30340","article-title":"Autophagy is induced in the skeletal muscle of cachectic cancer patients","volume":"6","author":"Aversa","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tem.2021.03.007_bb0565","doi-asserted-by":"crossref","first-page":"26991","DOI":"10.1038\/srep26991","article-title":"Aerobic exercise and pharmacological treatments counteract cachexia by modulating autophagy in colon cancer","volume":"6","author":"Pigna","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tem.2021.03.007_bb0570","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ajpath.2012.12.023","article-title":"Autophagic degradation contributes to muscle wasting in cancer cachexia","volume":"182","author":"Penna","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tem.2021.03.007_bb0575","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0165-6147(96)10021-3","article-title":"The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states","volume":"17","author":"Argiles","year":"1996","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tem.2021.03.007_bb0580","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/10409238.2013.857291","article-title":"Signaling pathways controlling skeletal muscle mass","volume":"49","author":"Egerman","year":"2014","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.tem.2021.03.007_bb0585","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1172\/JCI68523","article-title":"NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia","volume":"123","author":"He","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2021.03.007_bb0590","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semcdb.2016.02.009","article-title":"STAT3 in the systemic inflammation of cancer cachexia","volume":"54","author":"Zimmers","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.tem.2021.03.007_bb0595","doi-asserted-by":"crossref","first-page":"622","DOI":"10.15252\/emmm.201607052","article-title":"STAT3 promotes IFNgamma\/TNFalpha-induced muscle wasting in an NF-kappaB-dependent and IL-6-independent manner","volume":"9","author":"Ma","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.tem.2021.03.007_bb0600","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","article-title":"Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential","volume":"45","author":"Han","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.tem.2021.03.007_bb0605","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.drudis.2012.02.001","article-title":"Myostatin: more than just a regulator of muscle mass","volume":"17","author":"Argiles","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tem.2021.03.007_bb0610","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ccr.2010.10.020","article-title":"Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells","volume":"18","author":"Lee","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tem.2021.03.007_bb0615","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2004.06.006","article-title":"Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis","volume":"117","author":"Yang","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.tem.2021.03.007_bb0620","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(04)00211-4","article-title":"The IGF-1\/PI3K\/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors","volume":"14","author":"Stitt","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tem.2021.03.007_bb0625","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ncb1101-1009","article-title":"Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K\/Akt\/mTOR and PI(3)K\/Akt\/GSK3 pathways","volume":"3","author":"Rommel","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.tem.2021.03.007_bb0630","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/1078-0432.CCR-16-0495","article-title":"Molecular pathways: cachexia signaling-a targeted approach to cancer treatment","volume":"22","author":"Miyamoto","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tem.2021.03.007_bb0635","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clnu.2013.01.004","article-title":"A new look at an old drug for the treatment of cancer cachexia: megestrol acetate","volume":"32","author":"Argiles","year":"2013","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.tem.2021.03.007_bb0640","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1517\/14656560902960162","article-title":"Medroxyprogesterone acetate in the management of cancer cachexia","volume":"10","author":"Madeddu","year":"2009","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.tem.2021.03.007_bb0645","first-page":"255","article-title":"Megestrol in the treatment of AIDS associated cachexia. Evaluation by bioelectric impedance analysis of body composition","volume":"15","author":"Perez De Oteyza","year":"1998","journal-title":"An. Med. Interna"},{"key":"10.1016\/j.tem.2021.03.007_bb0650","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.critrevonc.2018.05.006","article-title":"Cancer cachexia: diagnosis, assessment, and treatment","volume":"127","author":"Sadeghi","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.tem.2021.03.007_bb0655","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.4081\/ejtm.2019.7960","article-title":"Therapeutic strategies against cancer cachexia","volume":"29","author":"Argiles","year":"2019","journal-title":"Eur. J. Transl. Myol."},{"key":"10.1016\/j.tem.2021.03.007_bb0660","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/cncr.22944","article-title":"A placebo-controlled double blind trial of etanercept for the cancer anorexia\/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group","volume":"110","author":"Jatoi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0665","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","article-title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients (N01C9)","volume":"68","author":"Jatoi","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0670","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1089\/jpm.2012.0146","article-title":"The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study","volume":"15","author":"Yennurajalingam","year":"2012","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.tem.2021.03.007_bb0675","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4103\/2277-9175.179182","article-title":"Pentoxifylline treatment in patients with cancer cachexia: a double-blind, randomized, placebo-controlled clinical trial","volume":"5","author":"Mehrzad","year":"2016","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.tem.2021.03.007_bb0680","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.tem.2021.03.007_bb0685","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jamda.2010.02.012","article-title":"Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia\/cachexia","volume":"12","author":"Chasen","year":"2011","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.tem.2021.03.007_bb0690","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2012.144","article-title":"Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma","volume":"106","author":"Prado","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0695","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tem.2021.03.007_bb0700","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132786","article-title":"TGF-beta blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia","volume":"10","author":"Greco","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tem.2021.03.007_bb0705","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.drudis.2008.10.010","article-title":"Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity","volume":"14","author":"Argiles","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tem.2021.03.007_bb0710","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/jcsm.12331","article-title":"LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial","volume":"9","author":"Golan","year":"2018","journal-title":"J. Cachex. Sarcopenia Muscle"},{"key":"10.1016\/j.tem.2021.03.007_bb0715","doi-asserted-by":"crossref","first-page":"E1967","DOI":"10.1210\/jc.2014-1271","article-title":"Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer","volume":"99","author":"Padhi","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2021.03.007_bb0720","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mus.23539","article-title":"A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers","volume":"47","author":"Attie","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tem.2021.03.007_bb0725","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.tem.2021.03.007_bb0730","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.12-5-594","article-title":"Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers","volume":"12","author":"Garcia","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.tem.2021.03.007_bb0735","first-page":"3495","article-title":"Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial","volume":"24","author":"Takayama","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0740","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tem.2021.03.007_bb0745","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","article-title":"ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia","volume":"28","author":"Currow","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tem.2021.03.007_bb0750","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/annonc\/mdq727","article-title":"Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial","volume":"22","author":"Brisbois","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tem.2021.03.007_bb0755","doi-asserted-by":"crossref","DOI":"10.1177\/1534735419881498","article-title":"The effects of dosage-controlled cannabis capsules on cancer-related cachexia and anorexia syndrome in advanced cancer patients: pilot study","volume":"18","author":"Bar-Sela","year":"2019","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.tem.2021.03.007_bb0760","first-page":"3029","article-title":"The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial","volume":"26","author":"Turcott","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0765","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hed.20662","article-title":"Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract","volume":"30","author":"Lai","year":"2008","journal-title":"Head Neck"},{"key":"10.1016\/j.tem.2021.03.007_bb0770","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00109-009-0547-z","article-title":"Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia","volume":"88","author":"Mantovani","year":"2010","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.tem.2021.03.007_bb0775","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clnu.2011.10.005","article-title":"Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib +\/- megestrol acetate for patients with cancer-related anorexia\/cachexia syndrome","volume":"31","author":"Madeddu","year":"2012","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.tem.2021.03.007_bb0780","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/jcsm.12126","article-title":"Espindolol for the treatment and prevention of cachexia in patients with stage III\/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial)","volume":"7","author":"Stewart Coats","year":"2016","journal-title":"J. Cachex. Sarcopenia Muscle"},{"key":"10.1016\/j.tem.2021.03.007_bb0785","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1158\/1078-0432.CCR-04-0373","article-title":"Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients","volume":"10","author":"Lindholm","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tem.2021.03.007_bb0790","doi-asserted-by":"crossref","first-page":"43202","DOI":"10.18632\/oncotarget.6439","article-title":"Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations","volume":"6","author":"Pin","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tem.2021.03.007_bb0795","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tem.2021.03.007_bb0800","first-page":"1269","article-title":"Phase I\/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy","volume":"22","author":"Greig","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.tem.2021.03.007_bb0805","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/SPC.0000000000000170","article-title":"The therapeutic potential of exercise to treat cachexia","volume":"9","author":"Lira","year":"2015","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.tem.2021.03.007_bb0810","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/SPC.0000000000000238","article-title":"Does physical exercise improve quality of life of advanced cancer patients?","volume":"10","author":"Navigante","year":"2016","journal-title":"Curr. Opin Support. Palliat. Care"},{"key":"10.1016\/j.tem.2021.03.007_bb0815","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tem.2021.03.007_bb0820","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific antibody based therapeutics: strengths and challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev."}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276021000680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276021000680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:41:26Z","timestamp":1760906486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276021000680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":164,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1043276021000680"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2021.03.007","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2021.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}